The problem with neoantigen prediction

Cancer vaccines have traditionally targeted tumor-associated self-antigens. More recently, however, attention has shifted to neoantigens. Targeting an individual's tumor-specific mutations is attractive because these peptides are new to the immune system and are not found in normal tissues. Com...

Full description

Saved in:

Bibliographic Details
Published in	Nature biotechnology Vol. 35; no. 2; p. 97
Main Author	Anon
Format	Journal Article
Language	English
Published	New York Nature Publishing Group US 01.02.2017 Nature Publishing Group
Subjects	631/154 631/61/212/2166 692/699/67/1059/2325 Agriculture Algorithms Antigens Antigens, Neoplasm Bioinformatics Biomedical and Life Sciences Biomedical Engineering/Biotechnology Biomedical Research Biomedicine Biotechnology Cancer Vaccines Computational Biology editorial Exome sequencing Humans Identification and classification Immune system Life Sciences Methods Models, Statistical Neoplasms - immunology Neoplasms - prevention & control Peptides Physiological aspects Proteins Software Tumor antigens Tumors
Online Access	Get full text
ISSN	1087-0156 1546-1696 1546-1696
DOI	10.1038/nbt.3800

Cover

More Information
Summary:	Cancer vaccines have traditionally targeted tumor-associated self-antigens. More recently, however, attention has shifted to neoantigens. Targeting an individual's tumor-specific mutations is attractive because these peptides are new to the immune system and are not found in normal tissues. Compared with tumor-associated self-antigens, neoantigens elicit T-cell responses not subject to host central tolerance in the thymus and also produce fewer toxicities arising from autoimmune reactions to non-malignant cells.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Editorial-2 ObjectType-Commentary-1
ISSN:	1087-0156 1546-1696 1546-1696
DOI:	10.1038/nbt.3800